128 related articles for article (PubMed ID: 12010825)
1. Janus kinase 3 inhibitor WHI-P131/JANEX-1 prevents graft-versus-host disease but spares the graft-versus-leukemia function of the bone marrow allografts in a murine bone marrow transplantation model.
Uckun FM; Roers BA; Waurzyniak B; Liu XP; Cetkovic-Cvrlje M
Blood; 2002 Jun; 99(11):4192-9. PubMed ID: 12010825
[TBL] [Abstract][Full Text] [Related]
2. Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice.
Cetkovic-Cvrlje M; Roers BA; Waurzyniak B; Liu XP; Uckun FM
Blood; 2001 Sep; 98(5):1607-13. PubMed ID: 11520814
[TBL] [Abstract][Full Text] [Related]
3. Treatment of post-bone marrow transplant acute graft-versus-host disease with a rationally designed JAK3 inhibitor.
Cetkovic-Cvrlje M; Roers BA; Schonhoff D; Waurzyniak B; Liu XP; Uckun FM
Leuk Lymphoma; 2002 Jul; 43(7):1447-53. PubMed ID: 12389628
[TBL] [Abstract][Full Text] [Related]
4. Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft-versus-host disease (GVHD) in a murine allogeneic bone marrow transplantation model.
Cetkovic-Cvrlje M; Uckun FM
Br J Haematol; 2004 Sep; 126(6):821-7. PubMed ID: 15352986
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the antigen-induced activation of rodent mast cells by putative Janus kinase 3 inhibitors WHI-P131 and WHI-P154 in a Janus kinase 3-independent manner.
Linwong W; Hirasawa N; Aoyama S; Hamada H; Saito T; Ohuchi K
Br J Pharmacol; 2005 Jul; 145(6):818-28. PubMed ID: 15852029
[TBL] [Abstract][Full Text] [Related]
6. [Effects of immature dendritic cells genetically modified to express sTNFR I on graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) in allogeneic bone marrow transplantation mice].
Wang SH; Li DP; Zhang YJ; Zhang P; Zeng LY; Pan XY; Xu KL; Huang YH
Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):88-93. PubMed ID: 22730654
[TBL] [Abstract][Full Text] [Related]
7. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents.
Sudbeck EA; Liu XP; Narla RK; Mahajan S; Ghosh S; Mao C; Uckun FM
Clin Cancer Res; 1999 Jun; 5(6):1569-82. PubMed ID: 10389946
[TBL] [Abstract][Full Text] [Related]
8. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
[TBL] [Abstract][Full Text] [Related]
9. Prevention of islet allograft rejection in diabetic mice by targeting Janus Kinase 3 with 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (JANEX-1).
Cetkovic-Cvrlje M; Dragt AL; Uckun FM
Arzneimittelforschung; 2003; 53(9):648-54. PubMed ID: 14558439
[TBL] [Abstract][Full Text] [Related]
10. In vivo toxicity and pharmacokinetic features of the janus kinase 3 inhibitor WHI-P131 [4-(4'hydroxyphenyl)-amino-6,7- dimethoxyquinazoline.
Uckun FM; Ek O; Liu XP; Chen CL
Clin Cancer Res; 1999 Oct; 5(10):2954-62. PubMed ID: 10537365
[TBL] [Abstract][Full Text] [Related]
11. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic nanoparticle constructs of a JAK3 tyrosine kinase inhibitor against human B-lineage ALL cells.
Uckun FM; Dibirdik I; Qazi S; Yiv S
Arzneimittelforschung; 2010; 60(4):210-7. PubMed ID: 20486472
[TBL] [Abstract][Full Text] [Related]
13. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation.
Tsukada N; Kobata T; Aizawa Y; Yagita H; Okumura K
Blood; 1999 Apr; 93(8):2738-47. PubMed ID: 10194454
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts.
Blazar BR; Taylor PA; Smith S; Vallera DA
Blood; 1995 Feb; 85(3):842-51. PubMed ID: 7833486
[TBL] [Abstract][Full Text] [Related]
15. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
[TBL] [Abstract][Full Text] [Related]
16. [Effect of Ly49A transfected mouse spleen cells on graft versus host disease and graft versus leukemia after haploidentical allogeneic bone marrow transplantation in mice].
Li Y; Guo K; Chen Y; Song Z; Li J; Deng L
Zhonghua Xue Ye Xue Za Zhi; 2002 Aug; 23(8):411-4. PubMed ID: 12411044
[TBL] [Abstract][Full Text] [Related]
17. Leucyl-leucine methyl ester-treated haploidentical donor lymphocyte infusions can mediate graft-versus-leukemia activity with minimal graft-versus-host disease risk.
Hsieh MH; Varadi G; Flomenberg N; Korngold R
Biol Blood Marrow Transplant; 2002; 8(6):303-15. PubMed ID: 12108916
[TBL] [Abstract][Full Text] [Related]
18. Prevention of DMBA-induced mammary gland tumors in mice by a dual-function inhibitor of JAK3 and EGF receptor tyrosine kinases.
Sahin K; Yabas M; Orhan C; Tuzcu M; Sahin TK; Ozercan IH; Qazi S; Uckun FM
Expert Opin Ther Targets; 2020 Apr; 24(4):379-387. PubMed ID: 32106727
[No Abstract] [Full Text] [Related]
19. Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-versus-leukemia reactivity, and tolerance after bone marrow transplantation.
Truitt RL; Atasoylu AA
Blood; 1991 Jun; 77(11):2515-23. PubMed ID: 2039833
[TBL] [Abstract][Full Text] [Related]
20. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation.
Cooke KR; Gerbitz A; Crawford JM; Teshima T; Hill GR; Tesolin A; Rossignol DP; Ferrara JL
J Clin Invest; 2001 Jun; 107(12):1581-9. PubMed ID: 11413166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
